Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCND2 | P30279 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | WEE1 | P30291 | 11/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633257 | 0.90 | WEE1 (0.53) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14633618 | 0.89 | JAK3 (0.61) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14633293 | 0.89 | WEE1 (0.58) | WEE1CYP3A4KCNH2FGFR4ALK | |
| SCHEMBL14633233 | 0.89 | WEE1 (0.63) | WEE1CYP3A4KCNH2FGFR4ALK | |
| SCHEMBL14633179 | 0.88 | WEE1 (0.53) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14633195 | 0.86 | JAK3 (0.55) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14632933 | 0.86 | WEE1 (0.52) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14633032 | 0.86 | PAK4 (0.56) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14633308 | 0.86 | JAK3 (0.53) | CDK4CCND1CCND2CCND3WEE1 | |
| SCHEMBL14632897 | 0.86 | CDK4 (0.48) | CDK4CCND1CCND2CCND3WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796289-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20130023523-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | claimed |
| US-9051327-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140296220-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-8796289-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013013031-A1 | PYRIDAZINO [4, 5 -D] PYRIMIDIN- (6H) -ONE INHIBITORS OF WEE - 1 KINASE | ABBVIE INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130023523-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296220-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | CDK4 31/4885CCND1 291/4885CCND2 396/4885 |
| US-20130023523-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | CDK4 31/4885CCND1 291/4885CCND2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.